Morgan Stanley's favorites: stocks with up to 90% chance of winning

Morgan Stanley's favorites: stocks with up to 90% chance of winning

According to a report by www.boerse-online.de, Morgan Stanley analysts expect cautiously optimistic growth in the market. Revenue growth of 1.7% is expected for the third quarter and EPS growth of 12% for 2024. In this context, the financial portal “TipRanks” has discovered two stocks that are particularly favored by Morgan Stanley analysts and offer price opportunities of at least 20 percent.

Morgan Stanley sees great potential in Cytokinetics as the company focuses on developing and commercializing muscle activators and muscle inhibitors to treat people with impaired muscle function. Although the company isn't profitable at the moment and is experiencing declining sales, it has drugs in late-stage development that show promise. Morgan Stanley analyst Jeffrey Hung rates the stock as overweight and gives it a price target of $60, which corresponds to a price opportunity of almost 90 percent.

LifeStance Health Group, a mental health company, is also favored by Morgan Stanley. The company expects double-digit sales growth and analyst Craig Hettenbach classifies the stock as overweight and sets the price target at ten dollars, which corresponds to a price chance of almost 75 percent.

Both companies have promising developments in their respective industries and could benefit from positive market trends. Morgan Stanley's recommendations could boost investor confidence and lead to increased trading volume in stocks, which could have a positive impact on the market and respective industries.